Titan Announces Q&A Session with Shareholders
2024年3月20日 - 8:30PM
Titan Medical Inc. (“
Titan”) (TSX: TMD; OTC:
TMDIF) announces that management will host a webcast Q&A
session on March 27, 2024 at 1:00 p.m. ET in connection with the
merger agreement entered into by Titan with Conavi Medical Inc.
(“
Conavi”), which was announced by press release
issued on March 18, 2024. Titan will provide prepared remarks
followed by a Q&A session. Paul Cataford, Interim President and
CEO and Chien Huang, Chief Financial Officer will attend the
session on behalf of Titan.
Shareholders are invited to submit questions in advance of the
Q&A session to investors@titanmedicalinc.com. Questions will be
accepted until March 25, 2024 at 1:00 pm ET. A link to the live
audio webcast will be made available on the "Investor Relations"
section of the Company’s website, www.titanmedicalinc.com.
About Titan Medical
Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a
medical technology company incorporated under the Business
Corporations Act (Ontario) and headquartered in Toronto, Ontario,
has developed an expansive patent portfolio related to the
enhancement of robotic assisted surgery (RAS), including through a
single access point, and is currently focused on evaluating new
opportunities to further develop and license its intellectual
property.
Cautionary Statement Regarding Forward-Looking
Information
This news release contains “forward-looking
statements” within the meaning of applicable Canadian and U.S.
securities laws, which reflect the current expectations of
management of Titan’s future growth, results of operations,
performance and business prospects and opportunities.
Forward-looking statements are frequently, but not always,
identified by words such as “may”, “would”, “could”, “will”,
“anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”,
“potential for” and similar expressions, although these words may
not be present in all forward-looking statements. Forward-looking
statements that appear in this release may include, without
limitation, references to: Titan will hold a Q&A session with
its CEO and CFO in attendance..
These forward-looking statements reflect
management’s current beliefs with respect to future events, and are
based on information currently available to management that, while
considered reasonable by management as of the date on which the
statements are made, are inherently subject to significant
business, economic and competitive uncertainties and contingencies
which could result in actions, events, conditions, results,
performance or achievements to be materially different from those
projected in the forward-looking statements. Forward-looking
statements involve significant risks, uncertainties and assumptions
and many factors could cause Titan’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements. Such factors and assumptions
include, but are not limited to, Titan’s ability to retain key
personnel; its ability to execute on its business plans and
strategies; its ability to continue to license some or all its
intellectual property to third parties and receive any material
consideration and other factors listed in the “Risk Factors”
section of Titan’s Annual Information Form for the fiscal year
ended December 31, 2022 (which may be viewed at www.sedarplus.com).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements.
Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions and Titan has
attempted to identify important factors that could cause actual
actions, events, conditions, results, performance or achievements
to differ materially from those described in forward-looking
statements, Titan cannot assure prospective investors that actual
results, performance or achievements will be consistent with these
forward-looking statements. Except as required by law, Titan
expressly disclaims any intention or obligation to update or revise
any forward-looking statements whether as a result of new
information, future events or otherwise. Accordingly, investors
should not place undue reliance on forward-looking statements. All
the forward-looking statements are expressly qualified by the
foregoing cautionary statements.
ContactTitan Medical
Inc. Chien
Huang Chief
Financial
Officer investors@titanmedicalinc.com
###
Titan Medical (TSX:TMD)
過去 株価チャート
から 12 2024 まで 1 2025
Titan Medical (TSX:TMD)
過去 株価チャート
から 1 2024 まで 1 2025